NCT07464028SuspendedPhase 2
Terazosin And Metabolic Energetics in Parkinson's Disease
Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This study investigates if Terazosin can improve metabolism in PD.
- Status (registry)
- Suspended
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 5 Mar 2026
- Start date
- 1 Jul 2028
- Primary completion date
- 1 Jul 2030
- Lead sponsor
- Ergun Y. Uc
- Diseases
- Parkinson disease
- NCT number
- NCT07464028
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Parkinson's disease
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.